NCT07552805

Brief Summary

The SENSE-ECO study is a prospective, randomized trial of 490 high-risk patients designed to show that the MultiSense® remote monitoring patch safely reduces hospital stays following major digestive surgery. By continuously tracking vital signs for five days at home, the device aims to maintain clinical safety and quality of life while decreasing overall healthcare costs for the French medical system.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
490

participants targeted

Target at P75+ for not_applicable

Timeline
18mo left

Started May 2026

Geographic Reach
1 country

5 active sites

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 31, 2026

Completed
27 days until next milestone

First Posted

Study publicly available on registry

April 27, 2026

Completed
21 days until next milestone

Study Start

First participant enrolled

May 18, 2026

Expected
1.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 17, 2027

2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

November 19, 2027

Last Updated

April 27, 2026

Status Verified

April 1, 2026

Enrollment Period

1.3 years

First QC Date

March 31, 2026

Last Update Submit

April 22, 2026

Conditions

Keywords

Remote monitoring

Outcome Measures

Primary Outcomes (2)

  • Mean CCI score of the Detailed Complications Index, calculated on the basis of complications recorded according to the Clavien-Dindo classification over a 30 day postoperative period for each of the two groups: the MultiSense group and Standard group

    The Clavien-Dindo classification is a system used in surgery to classify postoperative complications according to their severity

    30 days

  • The average length of the initial stay for both groups

    Up to 30 days

Secondary Outcomes (13)

  • Average CCI score from the Detailed Complications Index, calculated based on complications recorded according to the Clavien-Dindo classification over 8days, 15days, 30days and 90days post-surgery for each of the two groups: MultiSense® grp & Standad grp

    8days, 15days, 30days and 90days

  • Average number of deaths in each arm over 8 days, 15 days, 30 days and 90 days

    8 days, 15 days, 30 days and 90 days

  • Average total cumulative length of stay over 30 days

    30 days

  • Average number of hospital readmissions among patients receiving MultiSense® compared with patients receiving standard care, over a 30 days period; severity of the patient at readmission assessed using the Clavien-Dindo classification

    30 days

  • Patient quality of life scores assessed at baseline, on discharge from hospital and at 30 days using the fQoR-15 questionnaire

    30 days

  • +8 more secondary outcomes

Study Arms (2)

MultiSense® group

EXPERIMENTAL

Patients wearing the multisense® patch

Device: Monitoring by MultiSense®

Standard group

NO INTERVENTION

Patients following the standard care pathway

Interventions

The MultiSense device will be placed on the patient's back and will allow physicians to remotely monitor six biological parameters

MultiSense® group

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Adults (aged 18 and over)
  • Patients scheduled for gastrointestinal surgery :
  • Major gastrointestinal cancer surgery (pancreas, liver, stomach, oesophagus, rectum)
  • Colorectal surgery (rectal resection, surgery on the rectum and anus other than rectal resection, minor or major surgery on the small intestine and colon)
  • Patients in non-critical care with a high risk of post-surgical complications (ASA score 2 or 3)
  • Patients who have a personal mobile phone and Wi-Fi connectivity at home
  • Patients who provide written informed consent to participate in the study
  • Patients who are members of or beneficiaries of a social security scheme
  • Patients who are proficient in French

You may not qualify if:

  • Patients with a contraindication to the use of the device as described in the instructions for use (in particular: known skin allergy to adhesives or silicone, active implantable medical device such as a pacemaker or defibrillator, need for an MRI scan during the intended use of the device, intended application site of the device being tattooed, infected, ulcerated or damaged)
  • Any other condition which, in the investigator's opinion, would compromise the patient's safety or prevent compliance with the requirements of the protocol
  • Pregnant or breastfeeding patient
  • Adult under legal protection (under guardianship, curatorship or judicial protection)
  • Patient already participating in a clinical trial

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (5)

CHU de Nice

Nice, Alpes-Maritimes, 06000, France

Location

CHU de Besançon

Besançon, Doubs, 25000, France

Location

CHU Charles-Nicolle

Rouen, Seine-Maritime, 76000, France

Location

CHU Amiens-Picardie

Amiens, 80000, France

Location

Hôpital Cochin, AP-HP Centre

Paris, 75014, France

Location

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
OTHER
Intervention Model
PARALLEL
Model Details: 490 patients in total : 245 patients will wear the multisense patch and 245 will receive standard care
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 31, 2026

First Posted

April 27, 2026

Study Start (Estimated)

May 18, 2026

Primary Completion (Estimated)

September 17, 2027

Study Completion (Estimated)

November 19, 2027

Last Updated

April 27, 2026

Record last verified: 2026-04

Data Sharing

IPD Sharing
Will not share

Locations